KLI

Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin

Metadata Downloads
Abstract
Background/Aim: Oxaliplatin-based chemotherapy is associated with hepatic sinusoidal obstruction syndrome (SOS). Patients and Methods: We analyzed patients from two prospective trials, in which capecitabine/oxaliplatin (XELOX, 8 cycles; n=51) and S-1/oxaliplatin (SOX, continuous (SOX-C, n=50), or intermittent (discontinuation after cycle 6 and restart on progression, SOX-I, n=50)] were administered. We compared severity (splenomegaly, thrombocytopenia, liver enzyme levels, and hepatic parenchymal heterogeneity), clinical significance (delay or dose-reduction of chemotherapy), and reversibility of SOS (splenomegaly and thrombocytopenia after stopping chemotherapy) between SOX and XELOX in gastric cancer patients. Results: SOX was more likely to be associated with splenomegaly, thrombocytopenia, hyperbilirubinemia, and hepatic parenchymal heterogeneity than XELOX. Splenomegaly was partially reversible after stopping chemotherapy in both regimens, but recovery rate was lower in SOX. Proportion of delayed or dose-reduced chemotherapy cycles due to thrombocytopenia was significantly higher in SOX-C than in XELOX. Conclusion: S-I combination is more likely to worsen oxaliplatin-induced hepatic sinusoidal injuries than capecitabine in gastric cancer patients.
Author(s)
박숙련김문호서세영김어진김미정김민주
Issued Date
2021
Type
Article
Keyword
Gastric cancersinusoidal obstruction syndromeoxaliplatinS-1capecitabine
DOI
10.21873/anticanres.14788
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7843
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_crossref_primary_10_21873_anticanres_14788&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Comparison%20of%20Sinusoidal%20Obstruction%20Syndrome%20in%20Gastric%20Cancer%20Patients%20Receiving%20S-1%2Foxaliplatin%20Versus%20Capecitabine%2Foxaliplatin&offset=0&pcAvailability=true
Publisher
ANTICANCER RESEARCH
Location
그리스
Language
영어
ISSN
0250-7005
Citation Volume
41
Citation Number
1
Citation Start Page
391
Citation End Page
402
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.